Kim Ji Hye, Kang Minjung, Kang Eunjeong, Ryu Hyunjin, Jeong Yujin, Kim Jayoun, Park Sue K, Jeong Jong Cheol, Yoo Tae-Hyun, Kim Yaeni, Kim Yong Chul, Han Seung Seok, Lee Hajeong, Oh Kook-Hwan
Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Department of Internal Medicine, Ewha Womans University College of Medicine, Ewha Womans University Seoul Hospital, Seoul, Republic of Korea.
Kidney Res Clin Pract. 2023 Nov;42(6):700-711. doi: 10.23876/j.krcp.22.206. Epub 2023 Mar 22.
The 2009 Chronic Kidney Disease Epidemiology Collaboration creatinine-based estimated glomerular filtration rate (eGFRcr) equation contains a race component that is not based on biology and may cause a bias in results. Therefore, the 2021 eGFRcr and creatinine-cystatin C-based eGFR (eGFRcr-cysC) equations were developed with no consideration of race. This study compared the cardiovascular event (CVE) and all-cause mortality and CVE combined predictability among the three eGFR equations in Korean chronic kidney disease (CKD) patients.
This study included 2,207 patients from the KoreaN Cohort Study for Outcome in Patients With Chronic Kidney Disease. Receiver operating characteristic (ROC) and net reclassification improvement (NRI) index were used to compare the predictability of the study outcomes according to the 2009 eGFRcr, 2021 eGFRcr, and 2021 eGFRcr-cysC equations.
The overall prevalence of CVE and all-cause mortality were 9% and 7%, respectively. There was no difference in area under the curve of ROC for CVE and mortality and CVE combined among all three equations. Compared to the 2009 eGFRcr, both the 2021 eGFRcr (NRI, 0.013; 95% confidence interval [CI], - 0.002 to 0.028) and the eGFRcr-cysC (NRI, -0.001; 95% CI, -0.031 to 0.029) equations did not show improved CVE predictability. Similar findings were observed for mortality and CVE combined predictability with both the 2021 eGFRcr (NRI, -0.019; 95% CI, -0.039-0.000) and the eGFRcr-cysC (NRI, -0.002; 95% CI, -0.023 to 0.018).
The 2009 eGFRcr equation was not inferior to either the 2021 eGFRcr or eGFRcr-cysC equation in predicting CVE and the composite of mortality and CVE in Korean CKD patients.
2009年慢性肾脏病流行病学合作组织基于肌酐的估计肾小球滤过率(eGFRcr)方程包含一个并非基于生物学因素的种族成分,可能导致结果出现偏差。因此,2021年开发的eGFRcr方程以及基于肌酐-胱抑素C的eGFR(eGFRcr-cysC)方程在制定时未考虑种族因素。本研究比较了三种eGFR方程对韩国慢性肾脏病(CKD)患者心血管事件(CVE)、全因死亡率以及CVE合并情况的预测能力。
本研究纳入了来自韩国慢性肾脏病患者结局队列研究的2207例患者。采用受试者工作特征(ROC)曲线和净重新分类改善(NRI)指数,根据2009年eGFRcr、2021年eGFRcr和2021年eGFRcr-cysC方程比较研究结局的预测能力。
CVE和全因死亡率的总体患病率分别为9%和7%。在所有三个方程中,CVE、死亡率以及CVE合并情况的ROC曲线下面积没有差异。与2009年eGFRcr相比,2021年eGFRcr(NRI,0.013;95%置信区间[CI],-0.002至0.028)和eGFRcr-cysC(NRI,-0.001;95%CI,-0.031至0.029)方程在CVE预测能力方面均未显示出改善。对于死亡率以及CVE合并情况的预测能力,2021年eGFRcr(NRI,-0.019;95%CI,-0.039至0.000)和eGFRcr-cysC(NRI,-0.002;95%CI,-0.023至0.018)也有类似的发现。
在预测韩国CKD患者的CVE以及死亡率和CVE合并情况方面,2009年eGFRcr方程并不逊色于2021年eGFRcr方程或eGFRcr-cysC方程。